Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $20
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $40 to $20.
Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $40 to $20.